Autumn Glory Partners LLC Acquires 19,922 Shares of Novo Nordisk A/S (NYSE:NVO)

Autumn Glory Partners LLC grew its holdings in shares of Novo Nordisk A/S (NYSE:NVO) by 122.9% during the first quarter, according to its most recent 13F filing with the SEC. The institutional investor owned 36,130 shares of the company’s stock after buying an additional 19,922 shares during the period. Novo Nordisk A/S makes up 1.2% of Autumn Glory Partners LLC’s investment portfolio, making the stock its 21st largest holding. Autumn Glory Partners LLC’s holdings in Novo Nordisk A/S were worth $2,366,000 as of its most recent SEC filing.

A number of other institutional investors and hedge funds have also recently modified their holdings of the business. Advisory Resource Group boosted its holdings in shares of Novo Nordisk A/S by 21.0% during the 1st quarter. Advisory Resource Group now owns 14,503 shares of the company’s stock worth $1,007,000 after buying an additional 2,518 shares in the last quarter. Bay Colony Advisory Group Inc d b a Bay Colony Advisors lifted its stake in Novo Nordisk A/S by 34.0% during the 1st quarter. Bay Colony Advisory Group Inc d b a Bay Colony Advisors now owns 14,410 shares of the company’s stock valued at $999,000 after acquiring an additional 3,656 shares in the last quarter. Plimoth Trust Co. LLC lifted its stake in Novo Nordisk A/S by 4.3% during the 1st quarter. Plimoth Trust Co. LLC now owns 5,890 shares of the company’s stock valued at $409,000 after acquiring an additional 245 shares in the last quarter. HCR Wealth Advisors increased its position in shares of Novo Nordisk A/S by 23.6% during the 1st quarter. HCR Wealth Advisors now owns 14,483 shares of the company’s stock valued at $1,006,000 after purchasing an additional 2,763 shares during the last quarter. Finally, Bigelow Investment Advisors LLC purchased a new stake in shares of Novo Nordisk A/S during the 1st quarter valued at $200,000. 11.54% of the stock is currently owned by institutional investors.

Novo Nordisk A/S Price Performance

Shares of Novo Nordisk A/S stock opened at $74.03 on Thursday. The company has a debt-to-equity ratio of 0.70, a current ratio of 0.74 and a quick ratio of 0.56. The business’s 50 day simple moving average is $67.98 and its two-hundred day simple moving average is $79.17. The stock has a market capitalization of $332.19 billion, a P/E ratio of 21.90, a price-to-earnings-growth ratio of 1.33 and a beta of 0.66. Novo Nordisk A/S has a one year low of $57.00 and a one year high of $148.15.

Novo Nordisk A/S (NYSE:NVO) last announced its quarterly earnings results on Wednesday, May 7th. The company reported $0.92 EPS for the quarter, hitting analysts’ consensus estimates of $0.92. The business had revenue of $11.87 billion for the quarter. Novo Nordisk A/S had a return on equity of 80.94% and a net margin of 34.52%. Analysts forecast that Novo Nordisk A/S will post 3.84 EPS for the current year.

Wall Street Analyst Weigh In

Several brokerages have recently issued reports on NVO. BNP Paribas began coverage on Novo Nordisk A/S in a research report on Tuesday, April 15th. They set an “underperform” rating for the company. Stifel Nicolaus lowered Novo Nordisk A/S from a “buy” rating to a “hold” rating in a research report on Monday, March 3rd. Kepler Capital Markets raised Novo Nordisk A/S from a “hold” rating to a “buy” rating in a research report on Thursday, March 13th. BMO Capital Markets reissued a “market perform” rating and issued a $64.00 price objective (down previously from $105.00) on shares of Novo Nordisk A/S in a report on Thursday, April 17th. Finally, Guggenheim lowered Novo Nordisk A/S from a “strong-buy” rating to a “hold” rating in a report on Thursday, April 17th. Two equities research analysts have rated the stock with a sell rating, five have given a hold rating, four have assigned a buy rating and one has issued a strong buy rating to the stock. According to MarketBeat, Novo Nordisk A/S currently has an average rating of “Hold” and an average price target of $112.00.

About Novo Nordisk A/S

Novo Nordisk A/S, together with its subsidiaries, engages in the research and development, manufacture, and distribution of pharmaceutical products in Europe, the Middle East, Africa, Mainland China, Hong Kong, Taiwan, North America, and internationally. It operates in two segments, Diabetes and Obesity Care, and Rare Disease.